OCTOPUS: Ovarian Cancer Trials of Weekly Paclitaxel - Umbrella Study A Randomised, Phase II Umbrella Trial of a Weekly Paclitxel +/- Novel Agents in Platinum-Resistant Ovarian Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Vistusertib (Primary) ; Paclitaxel
- Indications Ovarian cancer
- Focus Therapeutic Use
- Acronyms OCTOPUS
- 06 Jun 2017 Trial design of the study presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 09 May 2017 Planned End Date changed from 7 Sep 2019 to 8 Dec 2019.
- 19 Feb 2016 Accrual to date is 0%, according to United Kingdom Clinical Research Network record.